Horror writers may have a hard time attracting those with aphantasia to read their spooky stories. A new study reveals those with aphantasia, a disorder marked by an inability to visualize mental imagery, have a hard time getting spooked by creepy stories. Findings suggest mental imagery may have a closer link to emotional processing and expression than previously believed.
Inducing hallucinations using visual stimuli in a lab setting enables more objective and reliable testing.
Face pareidolia, the phenomenon of seeing facelike structures in inanimate objects, is a perceptual phenomenon that occurs when sensory input is processed by visual mechanisms that have evolved to extract social content from human faces.
Aphantasia, a disorder in which people are lack the ability to mentally visualize imagery, is also associated with a widespread pattern of changes to other important cognitive processes. Many with aphantasia report a reduced ability to recall past events, imagine the future, and dream.
The strength of a person's mental imagery is associated with excitability in the prefrontal cortex and visual cortex. Highly excitable neurons in the visual cortex may reduce a person's ability to imagine mental images. The findings shed light on how aphantasia, a condition where a person can not imaging mental images, may occur.
Superagers, people aged 95 and older, showed more activation between their left and right frontoparietal control network in their brains than their younger counterparts. The superior connectivity contributed to better performance on visuospatial cognitive tasks, a new study reports.
Memory encoding processes important for decision making begin in the basolateral amygdala. The basolateral amygdala then creates cellular memories in the nucleus accumbens. The findings shed light on the learned connection between stimuli and reward.
Researchers have created the first genetic map of the cerebral cortex, which identifies over 300 genetic variants that influence the structure of the brain region.
New findings about dopaminergic neurons in the striatum could have implications for treating Parkinson's disease and Tourette syndrome.